Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Key claim: A phase 1b/2a open-label trial (RALLY-MF) is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and anemia response of DISC-0974 in patients with myelofibrosis or myelodysplastic syndrome and anemia.
Abstract
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
Why this matters
Anemia is a dominant driver of morbidity and treatment-limitation in PMF (especially the cytopenic subpopulation poorly served by ruxolitinib) and in MDS/MPN overlap syndromes, yet most current MF pipeline agents target splenomegaly or fibrosis rather than the hepcidin/iron axis. DISC-0974’s first formal clinical assessment in RALLY-MF introduces a mechanistically distinct, anemia-specific approach into the subtype-specific armamentarium, and its parallel enrollment of MF and MDS reinforces that anemia biology may be a unifying therapeutic axis across these adjacent subtypes.